The "Global Hypercalcemia Treatment Market" By Technology (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab, Calcimimetics), By Distribution Channel (Direct Tenders, Retail), By End User (Hospitals, Clinics), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024
The new report “Global Hypercalcemia Treatment Market” accounted to USD 76.9 billion in 2016 growing at a CAGR of 11.5% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Hypercalcemia is a condition caused due to high calcium level in the blood which leads to weak bones, kidney stones and also interferes in the functioning of heart and brain. Hypercalcemia treatment involves treatment of underlying diseases, restoring extracellular volume, correcting electrolyte deficiencies (potassium and magnesium), and reducing bone resorption.
Major Market Drivers and Restraints:
- Expanding label indications
- Increasing hip and knee replacement procedures will increase the risk of hypercalcemia
- Increasing surgical procedures
- Severe threat of damage to nervous system
Hypercalcemia Treatment Market Segmentation:
By technology the market forhypercalcemia treatment is segmented into bisphosphonates, calcitonin, glucocorticoids, denosumab, calcimimetics.
On the basis of distribution channel the market is segmented into direct and retail.
On the basis of end-users the hypercalcemia treatment market is segmented into hospitals and clinics.
On the basis of geography, hypercalcemia treatment market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.
In 2017, North America is expected to dominate the market.
Hypercalcemia Treatment Market Competitive Analysis:
The global hypercalcemia treatment market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares of hypercalcemia treatment market for global, Europe, North America, Asia Pacific and South America.
Hypercalcemia Treatment Market Major Market Competitors:
Some of the major players operating in hypercalcemia treatment market are AbbVie, Amgen, Merck, Novartis, and OPKO Health, DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio, Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd. and Cipla Inc, Bayer Pharma AG, Sun Pharmaceutical Industries Ltd.
Browse Full Report at databridgemarketresearch.com/repor…treatment-market/
Category: Market Research Publishers and RetailersCompany profile: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...
For more information: